Health
Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test – News-Medical.net
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce…
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with laboratory samples.
Avacta is developing several coronavirus tests using Affimer binders that are highly…
-
General17 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News24 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
General22 hours agoAustralia welcomes Gaza peace progress, hostage release
-
General15 hours agoHundreds attend justice march for Kaiden Morgan-Johnston in Morwell